Talphera (TLPH) stock price is $1.07, down 0.93% on the day, as of Oct 20, 2026. It has a market cap of $81.56Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap81.56 Mn
P/E-5.41
P/S81,561.50
Div. Yield0.00
Add ratio to table…
About
Talphera, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting the ubiquitin-proteasome system for the treatment of cancer and other serious diseases. The company's primary business activities involve researching and advancing small molecule drug candidates that modulate specific enzymes within the ubiquitin-proteasome pathway, with a lead focus on inhibitors of the deubiquitinating…
Talphera, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics targeting the ubiquitin-proteasome system for the treatment of cancer and other serious diseases. The company's primary business activities involve researching and advancing small molecule drug candidates that modulate specific enzymes within the ubiquitin-proteasome pathway, with a lead focus on inhibitors of the deubiquitinating enzyme USP1. Talphera operates within the biotechnology and pharmaceutical industry, specifically in the oncology and targeted therapy segments, leveraging scientific innovation to address unmet medical needs in hard-to-treat cancers.
Talphera generates revenue primarily through collaborations, licensing agreements, and potential future product sales once its therapeutic candidates receive regulatory approval. The company has entered into strategic partnerships with larger pharmaceutical entities to advance its pipeline, which may include upfront payments, milestone payments upon achieving predefined development or regulatory goals, and royalties on net sales of approved products. While currently pre-revenue from product sales, Talphera's revenue model is designed to monetize its intellectual property and research capabilities through alliances that provide non-dilutive funding and shared development risk, supporting its long-term goal of bringing targeted therapies to patients.
Talphera operates through the following segments:
Research and Development: This segment encompasses all activities related to the discovery, preclinical development, and clinical advancement of Talphera's therapeutic pipeline. The company focuses on identifying and optimizing small molecule compounds that inhibit key deubiquitinating enzymes, particularly USP1, to induce synthetic lethality in cancers with specific genetic vulnerabilities such as BRCA mutations. Talphera's lead product candidate, TP-0184, is a potent and selective oral inhibitor of USP1 currently being evaluated in clinical trials for patients with advanced solid tumors, including ovarian, breast, and pancreatic cancers.
Business Development and Partnerships: This segment manages external collaborations, licensing negotiations, and strategic alliances that support the company's research objectives and financial sustainability. Talphera engages in discussions with pharmaceutical and biotechnology companies to structure deals that may involve co-development, co-promotion, or out-licensing of its pipeline assets. These partnerships are designed to provide access to additional resources, expertise, and commercialization capabilities while allowing Talphera to retain significant rights to its innovations in certain territories or indications.
Talphera holds a niche but growing position within the competitive landscape of targeted cancer therapeutics, particularly in the emerging field of ubiquitin-proteasome system modulation. The company differentiates itself through its scientific expertise in deubiquitinating enzyme biology and its focus on USP1 inhibition as a precision medicine approach for genetically defined patient populations. While larger pharmaceutical companies such as Roche, Pfizer, and AstraZeneca also explore ubiquitin-related targets, Talphera competes by maintaining a specialized pipeline and agile research model, enabling rapid innovation in areas where broader oncology players may have less focus. Its competitive advantages include proprietary chemistry, deep mechanistic understanding of USP1-dependent synthetic lethality, and a clear regulatory path for its lead candidate in biomarker-selected populations.
Talphera serves patients with advanced solid tumors who have specific genetic alterations, particularly those with homologous recombination deficiency (HRD) such as BRCA1 or BRCA2 mutations. The company's therapeutic strategy is designed to benefit individuals suffering from recurrent or refractory ovarian, breast, pancreatic, and prostate cancers who have exhausted standard treatment options. While Talphera does not currently disclose specific named customers due to its pre-commercial stage, its eventual customers are expected to include oncology patients, healthcare providers administering infusion or oral therapies, and healthcare systems seeking effective treatments for genetically defined cancer subtypes.
Sector:HealthcareSector rationaleTalphera is a clinical-stage biopharmaceutical company that discovers and develops novel therapeutics, specifically small molecule drug candidates like TP-0184 for treating cancer. Its revenue model is based on pharmaceutical industry standards, including licensing agreements, milestone payments, and future product sales to healthcare providers and patients.Industry:BiotechnologyBiotechnologyPrimaryTalphera is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics, specifically small molecule drug candidates like TP-0184. Its revenue model relies on collaborations, licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.Classified using BQ-MICSCIK: 0001427925
Bull & bear
Investment Thesis
▲ Bull case
The company’s lead asset Nefamostat demonstrates a metabolism that is independent of hepatic or renal function which provides a mechanistic advantage over standard anticoagulants like heparin and citrate in critically ill patients with fluctuating organ function. This property translates into highly stable activated clotting times observed in the study with minimal need for dose titration after the initial hour. Such stability reduces nursing workload and lowers the risk of clotting related circuit interruptions which is a meaningful clinical benefit that could drive adoption once approved. The stability profile also supports a potential label expansion into other extracorporeal therapies where organ dysfunction is common. The Breakthrough Device Designation granted by the FDA underscores the agency’s recognition of unmet need and may facilitate a smoother review pathway. Together these scientific and regulatory attributes suggest the market may be undervaluing the product’s differentiation and long term upside.
Enrollment progress has surpassed the 50% milestone well ahead of schedule with over 90% of patients already recruited from sites that match the new target profile led by nephrologists. This high concentration of engaged investigators suggests that data quality will be robust and that the study is likely to meet its primary endpoint with a clear signal of efficacy. The company has indicated that top line data will be available within a month after the last patient is out which implies a rapid turnaround from completion to results. This speed reduces the window for potential delays and allows for a timely submission of a PMA targeting a potential approval in 2027. The ability to close the study quickly also preserves cash and limits additional operating expense burn. Investors may be underestimating how efficiently the trial is being executed and how quickly the data package could be assembled for regulatory review.
The financing structure includes two remaining conditional tranches totaling approximately sixteen million dollars that are expected to close upon achievement of study milestones such as top line data release and study completion. This milestone linked funding provides a non dilutive source of capital that aligns investor interest with operational success and reduces the likelihood of a cash shortfall before regulatory submission. Combined with the current cash balance of twenty one point one million dollars the company appears to have sufficient runway to cover operating expenses through the anticipated PMA filing date. The conditional nature of the tranches also creates a built in incentive for management to maintain rigorous study execution and cost discipline. Market participants may be overlooking how this financing mechanism de risks the balance sheet while preserving upside potential for shareholders.
Site feedback highlighted the simplicity of the Nefamostat administration protocol which mirrors the placebo and requires minimal monitoring after the initial hour leading to high satisfaction among nurses and investigators. This ease of use addresses a major pain point with existing anticoagulants where frequent lab testing and dose adjustments are necessary to maintain therapeutic range. The reduced nursing burden could translate into lower total cost of ownership for hospitals and make Nefamostat an attractive option for formulary inclusion. Moreover the positive qualitative data from sites may strengthen advocacy among key opinion leaders who influence purchasing decisions in the ICU setting. If these real world usability advantages are reflected in the final study analysis they could support a premium pricing strategy or faster uptake post approval.
Nefamostat exhibits broad spectrum activity that includes anti inflammatory and potential anti viral effects which may enable expansion into indications such as acute respiratory distress syndrome disseminated intravascular coagulation or acute pancreatitis. The company is also investigating a separate formulation referred to as LTX 608 for direct intravenous infusion that could be developed for these additional therapeutic areas. Success in any of these alternative uses would diversify revenue streams and reduce reliance on the CRRT market alone. The underlying pharmacology suggests a mechanistic rationale for benefit in conditions characterized by excessive protease activity. Market participants may be undervaluing the optionality embedded in the molecule’s multifunctional profile.
The company’s lead asset Nefamostat demonstrates a metabolism that is independent of hepatic or renal function which provides a mechanistic advantage over standard anticoagulants like heparin and citrate in critically ill patients with fluctuating organ function. This property translates into highly stable activated clotting times observed in the study with minimal need for dose titration after the initial hour. Such stability reduces nursing workload and lowers the risk of clotting related circuit interruptions which is a meaningful clinical benefit that could drive adoption once approved. The stability profile also supports a potential label expansion into other extracorporeal therapies where organ dysfunction is common. The Breakthrough Device Designation granted by the FDA underscores the agency’s recognition of unmet need and may facilitate a smoother review pathway. Together these scientific and regulatory attributes suggest the market may be undervaluing the product’s differentiation and long term upside.
Enrollment progress has surpassed the 50% milestone well ahead of schedule with over 90% of patients already recruited from sites that match the new target profile led by nephrologists. This high concentration of engaged investigators suggests that data quality will be robust and that the study is likely to meet its primary endpoint with a clear signal of efficacy. The company has indicated that top line data will be available within a month after the last patient is out which implies a rapid turnaround from completion to results. This speed reduces the window for potential delays and allows for a timely submission of a PMA targeting a potential approval in 2027. The ability to close the study quickly also preserves cash and limits additional operating expense burn. Investors may be underestimating how efficiently the trial is being executed and how quickly the data package could be assembled for regulatory review.
The financing structure includes two remaining conditional tranches totaling approximately sixteen million dollars that are expected to close upon achievement of study milestones such as top line data release and study completion. This milestone linked funding provides a non dilutive source of capital that aligns investor interest with operational success and reduces the likelihood of a cash shortfall before regulatory submission. Combined with the current cash balance of twenty one point one million dollars the company appears to have sufficient runway to cover operating expenses through the anticipated PMA filing date. The conditional nature of the tranches also creates a built in incentive for management to maintain rigorous study execution and cost discipline. Market participants may be overlooking how this financing mechanism de risks the balance sheet while preserving upside potential for shareholders.
Site feedback highlighted the simplicity of the Nefamostat administration protocol which mirrors the placebo and requires minimal monitoring after the initial hour leading to high satisfaction among nurses and investigators. This ease of use addresses a major pain point with existing anticoagulants where frequent lab testing and dose adjustments are necessary to maintain therapeutic range. The reduced nursing burden could translate into lower total cost of ownership for hospitals and make Nefamostat an attractive option for formulary inclusion. Moreover the positive qualitative data from sites may strengthen advocacy among key opinion leaders who influence purchasing decisions in the ICU setting. If these real world usability advantages are reflected in the final study analysis they could support a premium pricing strategy or faster uptake post approval.
Nefamostat exhibits broad spectrum activity that includes anti inflammatory and potential anti viral effects which may enable expansion into indications such as acute respiratory distress syndrome disseminated intravascular coagulation or acute pancreatitis. The company is also investigating a separate formulation referred to as LTX 608 for direct intravenous infusion that could be developed for these additional therapeutic areas. Success in any of these alternative uses would diversify revenue streams and reduce reliance on the CRRT market alone. The underlying pharmacology suggests a mechanistic rationale for benefit in conditions characterized by excessive protease activity. Market participants may be undervaluing the optionality embedded in the molecule’s multifunctional profile.
The study’s enrollment is dependent on a narrow patient population consisting of adults undergoing CRRT who cannot tolerate heparin or are at risk for bleeding which limits the absolute number of eligible subjects and may slow recruitment despite current progress. Any shortfall in qualifying patients could push the completion date beyond the anticipated second half of 2026 and delay the top line data readout. The company has acknowledged that enrollment flows in ebbs and flows and that it remains reliant on the variability of patient arrivals at participating sites. This dependency introduces uncertainty into the timeline and increases the risk that the projected 2027 PMA submission could slip further. Investors who assume a smooth enrollment trajectory may be underestimating the potential for stochastic delays.
The financing plan relies on two conditional tranches totaling approximately sixteen million dollars that are only released if specific milestones such as top line data release and study completion are achieved. If the study fails to meet its primary endpoint or encounters regulatory setbacks these tranches may not close leaving the company with a cash runway that could be shorter than anticipated. The current cash balance of twenty one point one million dollars while sufficient for near term operations may not cover a prolonged delay or additional studies needed to address any deficiencies identified in the NEPHRO CRRT trial. This creates a financing gap risk that could force dilutive fundraising or force a strategic reassessment. Market participants may be overconfident in the certainty of the conditional funding and overlook the downside scenario where milestones are missed.
Although Nefamostat has a favorable metabolic profile the drug’s mechanism as a serine protease inhibitor carries an inherent bleeding risk that must be weighed against its anticoagulant benefit. In critically ill patients even a modest increase in bleeding propensity can lead to serious clinical events such as hemorrhagic complications or transfusion requirements. The study’s primary endpoint focuses on clotting time and does not directly capture safety outcomes which means that adverse bleeding events could emerge only after approval or in post marketing surveillance. If safety concerns arise the product could face label restrictions dosage limitations or even withdrawal which would severely impair commercial prospects. Investors focusing solely on efficacy may be neglecting the safety overhang that could undermine the product’s risk reward profile.
The market for regional anticoagulants in CRRT is relatively niche with the total addressable population estimated in the low tens of thousands of patients annually in the United States. Even if Nefamostat captures a significant share of this limited pool the revenue potential may be modest compared to broader therapeutic areas. The company’s reliance on a single indication exposes it to concentration risk where any setback in CRRT adoption or reimbursement could disproportionately affect earnings. Additionally the presence of established anticoagulants such as heparin and citrate which are low cost and deeply entrenched in ICU practice creates a high barrier to entry for a new entrant. Market participants may be overestimating the uptake speed and underestimating the incumbent advantage and pricing pressure that could limit profitability.
The company’s operating expenses have risen year over year with research and development costs increasing from one million one hundred sixty nine thousand to one million six hundred fifty thousand and selling general and administrative expenses rising from one million seven hundred seventy four thousand to two million two hundred ninety eight thousand. This upward trend in cash burn suggests that the business is consuming capital at an accelerating pace even before any product revenue is generated. If the study does not produce a positive outcome the continued expense growth could erode the existing cash cushion and necessitate additional financing on less favorable terms. The lack of any recurring revenue stream means that the company’s financial sustainability is entirely contingent on the success of Nefamostat. Investors may be downplaying the impact of persistent operating losses on the balance sheet and the potential dilution that could follow.
The study’s enrollment is dependent on a narrow patient population consisting of adults undergoing CRRT who cannot tolerate heparin or are at risk for bleeding which limits the absolute number of eligible subjects and may slow recruitment despite current progress. Any shortfall in qualifying patients could push the completion date beyond the anticipated second half of 2026 and delay the top line data readout. The company has acknowledged that enrollment flows in ebbs and flows and that it remains reliant on the variability of patient arrivals at participating sites. This dependency introduces uncertainty into the timeline and increases the risk that the projected 2027 PMA submission could slip further. Investors who assume a smooth enrollment trajectory may be underestimating the potential for stochastic delays.
The financing plan relies on two conditional tranches totaling approximately sixteen million dollars that are only released if specific milestones such as top line data release and study completion are achieved. If the study fails to meet its primary endpoint or encounters regulatory setbacks these tranches may not close leaving the company with a cash runway that could be shorter than anticipated. The current cash balance of twenty one point one million dollars while sufficient for near term operations may not cover a prolonged delay or additional studies needed to address any deficiencies identified in the NEPHRO CRRT trial. This creates a financing gap risk that could force dilutive fundraising or force a strategic reassessment. Market participants may be overconfident in the certainty of the conditional funding and overlook the downside scenario where milestones are missed.
Although Nefamostat has a favorable metabolic profile the drug’s mechanism as a serine protease inhibitor carries an inherent bleeding risk that must be weighed against its anticoagulant benefit. In critically ill patients even a modest increase in bleeding propensity can lead to serious clinical events such as hemorrhagic complications or transfusion requirements. The study’s primary endpoint focuses on clotting time and does not directly capture safety outcomes which means that adverse bleeding events could emerge only after approval or in post marketing surveillance. If safety concerns arise the product could face label restrictions dosage limitations or even withdrawal which would severely impair commercial prospects. Investors focusing solely on efficacy may be neglecting the safety overhang that could undermine the product’s risk reward profile.
The market for regional anticoagulants in CRRT is relatively niche with the total addressable population estimated in the low tens of thousands of patients annually in the United States. Even if Nefamostat captures a significant share of this limited pool the revenue potential may be modest compared to broader therapeutic areas. The company’s reliance on a single indication exposes it to concentration risk where any setback in CRRT adoption or reimbursement could disproportionately affect earnings. Additionally the presence of established anticoagulants such as heparin and citrate which are low cost and deeply entrenched in ICU practice creates a high barrier to entry for a new entrant. Market participants may be overestimating the uptake speed and underestimating the incumbent advantage and pricing pressure that could limit profitability.
The company’s operating expenses have risen year over year with research and development costs increasing from one million one hundred sixty nine thousand to one million six hundred fifty thousand and selling general and administrative expenses rising from one million seven hundred seventy four thousand to two million two hundred ninety eight thousand. This upward trend in cash burn suggests that the business is consuming capital at an accelerating pace even before any product revenue is generated. If the study does not produce a positive outcome the continued expense growth could erode the existing cash cushion and necessitate additional financing on less favorable terms. The lack of any recurring revenue stream means that the company’s financial sustainability is entirely contingent on the success of Nefamostat. Investors may be downplaying the impact of persistent operating losses on the balance sheet and the potential dilution that could follow.